Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2013. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs) regarding their personal holdings in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on shareholding changes resulting from a dividend reinvestment.
Material Changes
The filing details an increase in share interests for specific directors and connected persons following the reinvestment of the dividend paid on October 3, 2013. The transaction price was 1,566.6515 pence per Ordinary Share. Specific increases include:
- Sir Andrew Witty: 2,402 shares
- Lady C Witty: 1,680 shares
- Mr I W Whyte: 119 shares
- Mrs V A Whyte: No change reported
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of director share transactions in accordance with Disclosure and Transparency Rules 3.1.4R(1)(a) and (c).
Investor Verification Points
- Verify the dividend reinvestment price of 1,566.6515 pence per share against market data for October 3, 2013.
- Confirm the total shareholding positions of Sir Andrew Witty and other named directors post-transaction.
- Review the company's Form 20-F for comprehensive financial performance data, as this 6-K contains no financial statements.